Cuba has had a vaccine for Lung Cancer since 2011, and now it's coming to the U.S.
Believe it or not, there has been a lung cancer vaccine (CIMAvax) available for over half a decade.
A trade embargo has prevented it from entering U.S. borders. That was until in 2015 when New York Governor Andrew Cuomo and a dozen New York industry leaders organized a trade mission to Cuba in order to capitalize on getting the lung cancer vaccine into the U.S.
The trip began the process of mending our trade relations with Cuba and has given U.S. researchers the opportunity to conduct medical trials on the vaccine. The trials are being conducted at Roswell Park Cancer Institute in Buffalo, NY and, while they are in the early stages, the results thus far have been promising.
In 2007 a study on stage III and IV lung cancer patients given CIMAvax showed that the vaccine was safe and that it had significantly increased tumor-reducing antibodies in more than half of the cases.
It proved to be noticeably more effective in patients under 60.
Since 2011 CIMAvax has been administered to about five thousand people, one thousand of which reside in Cuba.
The Cuban government has stated that it only costs about a dollar to manufacture the vaccine so when your doctor charges you well over a grand for it you will have right to be angry but, ultimately, this will save a great deal of lives and for that we should be thankful.
Below is a video with a quick a explanation of how the CIMAvax vaccine works:
If you enjoyed this article or learned something new, please don't forget to share it with others so they have a chance to enjoy this free information. This article is open source and free to reblog or use if you give a direct link back to the original article URL. Thanks for taking the time to support an open source initiative. We believe all information should be free and available to everyone. Have a good day and we hope to see you soon!
Cuba has had a vaccine for Lung Cancer since 2011, and now it's coming to the U.S. Reviewed by Jamm Real on 13:41:00 Rating: